[ 68 Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series
Journal of Nuclear Medicine · 2024-10 · 65 (10) · 1597-1603
DOI: 10.2967/jnumed.124.268147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 12.09.2024. Verfasst von Alex J Poot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Glypicans, Radiopharmaceuticals. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
To date, the imaging and diagnosis of hepatocellular carcinoma (HCC) rely on CT/MRI, which have well-known limitations. Glypican-3 (GPC3) is a cell surface receptor highly expressed by HCC but not by normal or cirrhotic liver tissue. Here we report initial clinical results of GPC3-targeted PET imaging with [68Ga]Ga-DOTA-RYZ-GPC3 (RAYZ-8009), a peptide-based GPC3 ligand in patients with known or suspected HCC. Methods: [68Ga]Ga-RAYZ-8009 was obtained after labeling the peptide precursor with 68Ga from a 68Ge/68Ga generator and heating at 90°C for 10 min followed by sterile filtration. After administration of [68Ga]Ga-RAYZ-8009, a dynamic or static PET/CT scan was acquired between 45 min and 4 h after administration. Radiotracer uptake was measured by SUVs for the following tissues: suspected or actual HCC or hepatoblastoma lesions, non-tumor-bearing liver, renal cortex, blood pool in the left ventricle, and gastric fundus. Additionally, tumor-to-healthy-liver ratios (TLRs) were calculated. Results: Twenty-four patients (5 patients in the dynamic protocol; 19 patients in the static protocol) were scanned. No adverse events occurred. Two patients had no lesion detected and did not have HCC during follow-up. In total, 50 lesions were detected and analyzed. The mean SUVmax of these lesions was 19.6 (range, 2.7-95.3), and the mean SUVmean was 10.1 (range, 1.0-49.2) at approximately 60 min after administration. Uptake in non-tumor-bearing liver and blood pool rapidly decreased over time and became negligible 45 min after administration (mean SUVmean,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands.
- Radiology and Nuclear Medicine, Princess Máxima Center, Utrecht, The Netherlands.
- Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Bavarian Cancer Research Center, Munich, Germany.
- Department of Nuclear Medicine, School of Medicine and Health, TUM Klinikum, Technical University of Munich, Munich, Germany; and.
- Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands; a.j.a.t.braat@umcutrecht.nl.
Zitieren
APA
Poot, A. J., Lapa, C., Weber, W. A., Lam, M. G. E. H., Eiber, M., Dierks, A., Bundschuh, R. A., & Braat, A. J. A. T. (2024). [ 68 Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series. Journal of Nuclear Medicine, 65(10), 1597-1603. https://doi.org/10.2967/jnumed.124.268147
Vancouver
Poot AJ, Lapa C, Weber WA, Lam MGEH, Eiber M, Dierks A, et al. [ 68 Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series. Journal of Nuclear Medicine. 2024;65(10):1597-1603. doi:10.2967/jnumed.124.268147
BibTeX
@article{Poot2024,
author = {Poot, Alex J and Lapa, Constantin and Weber, Wolfgang A and Lam, Marnix G E H and Eiber, Matthias and Dierks, Alexander and Bundschuh, Ralph A and Braat, Arthur J A T},
title = {[ 68 Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {10},
pages = {1597--1603},
doi = {10.2967/jnumed.124.268147}
}
EUVIMED